GHK-Cu

67% of identified publications used preclinical animal models, mostly rats, showing variable effects on tendon, muscle, bone, and ligament healing.; Human clinical studies were few, lacked robust controls, and showed at best modest improvements for metabolic bone health and degenerative knee pain.; Some peptides, such as MK-677, were associated with significant risks including congestive heart failure and metabolic dysfunction like insulin resistance.; Due to lack of robust efficacy and safety data, peptide supplements are not currently recommended for musculoskeletal recovery or performance enhancement.

Therapeutic peptides are effective for type 2 diabetes and obesity treatment.; Peptides show potential for skin rejuvenation and as hormone analogs.; Novel unapproved peptides are expanding into preventive medicine and performance enhancement.; More research is required to ensure safe human use of most new peptides.

BPC-157 showed potential in tendon and muscle repair but lacks validation in human trials.; TB-4 and TB-500 promoted angiogenesis in preclinical models, but human orthopaedic data are absent.; CJC-1295 with ipamorelin improved muscle tension in murine models, limited to animal studies.; No clinical evidence supports GHK-Cu or tesamorelin for musculoskeletal conditions.

GHK-Cu was successfully loaded onto hydroxyapatite microspheres by electrostatic adsorption.; GHK-Cu@CMHA gel exhibited sustained release of GHK-Cu for 7 days with good flowability and injectability.; In LPS-induced inflammation models, GHK-Cu@CMHA reduced inflammatory factors and ROS levels while increasing SOD activity.; H&E and Masson staining showed significant collagen deposition, confirming anti-inflammatory and antioxidant properties.

GHK-Cu reduced weight loss, DAI, colonic edema, and inflammatory damage in DSS-induced UC mice.; GHK-Cu upregulated ZO-1 and Occludin expression, promoting mucosal healing in a co-culture model.; GHK-Cu increased SIRT1 and decreased p-STAT3 expression; STAT3 silencing abolished its effects on healing and tight junction proteins.; GHK-Cu suppressed inflammatory cytokines and RORγt expression, indicating potential Th17 cell reduction.

GHK-HA conjugates bind copper(II) ions and potentiate the properties of HA and GHK in vitro.; Copper promotes expression and release of BDNF, VEGF, and BMP-2.; Protective and regenerative activities involve translocation of CCS and Atox1 to the nucleus as transcription factors.

GHK-Cu is a hydrophilic compound with limited permeation through the lipophilic stratum corneum.; Liposomes may improve GHK-Cu's skin permeation potential.; Literature shows little attention to transport of liposomes containing GHK-Cu.; This research gap drives need for new methods to evaluate liposome effects on GHK-Cu transportation.

GHK-Cu binds to peroxiredoxin 6 (PRDX6) to reduce lung inflammation and fibrosis in silicosis mice.; GHK-Cu inhibits crystalline silica-induced oxidative stress in alveolar macrophages.; No significant systemic toxicity was observed with GHK-Cu treatment.; GHK-Cu attenuates progression of pulmonary inflammation and fibrosis in silicosis.

What is GHK-Cu?

GHK-Cu (copper tripeptide-1) is a naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) that exerts its effects primarily through modulation of gene expression and extracellular matrix remodeling. Its mechanism involves chelating copper ions, which facilitates activation of matrix metalloproteinases (M

How does GHK-Cu work?

Copper-binding tripeptide that stimulates collagen synthesis, wound healing, and remodeling gene expression.

What is the research status of GHK-Cu?

GHK-Cu is currently classified as preclinical, with 80 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of GHK-Cu?

GHK-Cu has a molecular weight of approximately 400.9 g/mol (formula C14H21CuN6O4-).